secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verona Pharma plc (—)
CIK:        0001657312
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001657312-24-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verona Pharma reports Q1 net loss $25.8M; PDUFA for ensifentrine June 26, secures $650M financing
--------------------------------------------------------------------------------

- Net loss $25.8M for Q1 2024 vs $16.7M in Q1 2023; SG&A costs rose to $20.4M on launch prep.
- Cash and equivalents $254.9M at March 31, 2024; new $650M strategic financing available.
- PDUFA target date for ensifentrine (COPD) is June 26, 2024; no advisory committee planned.
- R&D expenses fell to $6.8M (Q1 2023: $12.6M) as ENHANCE Phase 3 program completed in 2023.
- If approved, commercial launch in US expected Q3 2024; Phase 2 trials in COPD combo and bronchiectasis planned H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1657312/000165731224000011/0001657312-24-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1657312/000165731224000011/vrna-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001657312-24-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer